Article Per Year (5 Year)
p-Index From 2020 - 2025
0.659
P-Index
This Author published in this journals
All Journal Journal of the Medical Sciences (Berkala Ilmu Kedokteran) JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Indonesian Journal of Cancer
Hanafi, Arif Riswahyudi
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
CEA and Cyfra 21-1 linked to serial miRNA expressions of advanced-stage non-small cell lung cancer in Indonesia Hanafi, Arif Riswahyudi; Jayusman, Achmad Mulawarman; Imelda, Priscillia; Alfasunu, Serafim; Sadewa, Ahmad Hamim; Pramono, Dibyo; Heriyanto, Didik Setyo; Haryana, Sofia Mubarika; Kresno, Siti Boedina
Journal of the Medical Sciences (Berkala Ilmu Kedokteran) Vol 55, No 4 (2023)
Publisher : Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.19106/JMedSci005504202303

Abstract

Globally, lung cancer is one of the cancers leading to dead, dominated by non-small cell lung cancer (NSCLC). In a previous study has shown those serial miRNA expressions (miR-148, miR-34, miR-222, and miR-155) had prognostic value in advanced-stage NSCLC patients. Meanwhile, CEA and Cyfra 21-1, pulmonary tumor markers, are sometimes considered in the Department of Pulmonology, Dharmais Cancer Hospital, Jakarta, although they are not used in routine clinics for prognostication. Both miRNA and CEA-Cyfra 21-1 are valuable biomarkers in NSCLC. This study aimed to evaluate their correlation between CEA and/or Cyfra 21-1 with miRNA expressions in NSCLC patients. It was a cohort retrospective study using data from the previous study. The correlation between variables was analyzed by Spearman-rho. A positive correlation was observed between CEA and Cyfra 21-1 with miR-148, miR-222, and miR-155 [(CEA: p=0.00369, r=0.522; p=0.00242, r=0.542; p 0.00106, r=0.576) (Cyfra: 21-1= p 0.01252, r=0.378; p=0.00035, r=0.519; p=0.01532, r=0.368)]. In conclusion, CEA and Cyfra 21-1 correlate with miR-148, miR-222, and miR-155 expressions in advanced-stage NSCLC.
Diagnostic Accuracy of Modalities for Diagnosis of Thoracic Cancer: Retrospective Analysis Ariawan, Wily Pandu; Hanafi, Arif Riswahyudi; Pradipta, Jaka; Jayusman, Mulawarman; Hanif, Muhammad Alfin; Hutabarat, Jubillete Windy; Amira, Salsabila Nur
Indonesian Journal of Cancer Vol 19, No 3 (2025): September
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i3.1307

Abstract

Background: Thoracic cancer becomes a huge consideration, especially for lung cancer, because it quietly increases over time and needs highly sensitive diagnostic modalities. Thus, we aim to investigate the diagnostic accuracy of several cytology-based modalities to diagnose thoracic cancer. It would serve as a reference for other cancer centers in estimating diagnostic approaches for thoracic cancer.Method: Retrospective analysis with a cross-sectional study comprised of 2358 diagnostic procedures at Dharmais Cancer Hospital, Jakarta, Indonesia, from 2020 to 2023. Data were extracted from e-medical records. We compared seven cytology-based procedures to the gold standard, which is histopathology examination. Results: Study subjects (n=2358; mean age 60 ± 12.0; 62.6% male) predominantly used the mode of diagnostic Bronchial Brushing Cytology (BBC) about 676 (28.7%). Endobronchial Ultrasound (EBUS) was the highest sensitivity (88.1%) of the diagnostic approach for thoracic cancer (p 0.05).Conclusion: EBUS had the highest sensitivity in diagnosing thoracic cancer. However, multimodality diagnostic procedures should be considered for patients who have symptoms suggestive of thoracic cancer to get highly positive results and lower complications, both cytologically and histologically. As a national cancer center, providing data on diagnostic modalities is necessary, and an analysis of cancer services is required for informed policy recommendations.
Profile of Dermatologic Side Effects of Tyrosine Kinase Inhibitor (EGFR-TKIs) in Lung Cancer Patients Napitupulu, Elfrida; Nurrochmad, Arief; Hanafi, Arif Riswahyudi; Wahyudi, Danang Tri
JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) Vol 14, No 3
Publisher : Faculty of Pharmacy, Universitas Gadjah Mada

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/jmpf.91322

Abstract

Background: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKIs) drugs are commonly used target therapies in patients with advanced-stage non-small cell carcinoma lung cancer (NSCLC).Objectives: This study aims to provide an overview of dermatologic side effects and quality of life index of NSCLC patients who received EGFR-TKIs targeted therapy at Dharmais Cancer Hospital.Methods: This study used a cross-sectional design. Inclusion criteria were patients who received EGFR-TKIs targeted therapy, namely gefitinib, erlotinib, and afatinib, in September - October 2023, who were willing to be research subjects, and patients who were not in a medical emergency. In total, 52 patients filled out the dermatology life quality index (DLQI) questionnaire through interviews and medical records. Data evaluation was performed descriptively in the form of percentages.Results: The most common occurrence of dermatologic side effects was skin hypersensitivity reactions with mild severity (grade 1) by 59.6%, moderate severity (grade 2) by 19.2%, and severe severity (grade 3) by 1.9%, and no drug dermatologic side effects by 19.2%. In comparison, the most DLQI was in the category of not affecting patient life. In general, side effects with moderate (grade 2) and severe (grade 3). The severity will decrease to mild severity (grade 1) when already getting topical corticosteroid drugs or combinations with oral antibiotics and antihistamine drugs.Conclusion: The most severe side effect was grade 1, which slightly affected the patient's quality of life. Education and monitoring of side effects and management of symptoms are necessary to reduce the severity and improve patients' quality of life.
Co-Authors Ahmad Hamim Sadewa Alfasunu, Serafim Amira, Salsabila Nur Ariawan, Wily Pandu Arief Nurrochmad Dibyo Pramono Didik Setyo Heriyanto Hanif, Muhammad Alfin Hutabarat, Jubillete Windy Imelda, Priscillia Jayusman, Achmad Mulawarman Jayusman, Mulawarman Napitupulu, Elfrida Pradipta, Jaka Siti Boedina Kresno Sofia Mubarika Haryana Wahyudi, Danang Tri